$OGEN ON THE WATCHLIST FOR BREAKOUT IN ORAGENICS INC
******HOT STOCK ON THE WATCHLIST FOR A SWING TRADE IN THE WEEKS TO COME, SPECULATION AND RUMORS HAVE BROUGHT IT THE ATTENTION OF MANY AND SOME ACCUMULATION HAS STARTED TO TAKE PLACE. JUST LIKE MOST BIO STOCKS, 
OGEN TENDS TO MOVE VERY FAST FOR GREAT GAINS ON TRIAL AND DATA RELEASE, SO SET YOUR ALERTS FOR SPIKES.
AVERAGE ANALYSTS PRICE TARGET $2.50
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of lantibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
OGEN TENDS TO MOVE VERY FAST FOR GREAT GAINS ON TRIAL AND DATA RELEASE, SO SET YOUR ALERTS FOR SPIKES.AVERAGE ANALYSTS PRICE TARGET $2.50
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of lantibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.